عنوان
پدید آورنده
موضوع
رده
RM 301.25 .B37 2013
RM
301
.
25
.
B37
2013
کتابخانه
محل استقرار
INTERNATIONAL STANDARD BOOK NUMBER
(Number (ISBN
0124071805 (pbk.)
(Number (ISBN
9780124071803 (pbk.)
NATIONAL BIBLIOGRAPHY NUMBER
Number
dltt
TITLE AND STATEMENT OF RESPONSIBILITY
Title Proper
The Future of Drug Discovery :
General Material Designation
[Book]
Other Title Information
Who Decides Which Diseases to Treat? /
First Statement of Responsibility
Tamas Bartfai, Graham V. Lees.
PHYSICAL DESCRIPTION
Specific Material Designation and Extent of Item
xxx, 346 pages :
Other Physical Details
illustrations ;
Dimensions
23 cm
GENERAL NOTES
Text of Note
Includes index.
CONTENTS NOTE
Text of Note
Introduction -- Why there will be new drugs despite the ongoing 'crisis' of drug development in Big Pharma -- The need for medicines grows -- Medicines are becoming better: some of the breakthrough medicines of the past decades -- Which diseases do we want to treat? -- Therapeutic areas: strategically important diseases of the future -- Blockbuster proprietary drugs versus generic drugs -- Why is pharma a special industry? -- Diagnosing toward personalized medicine -- Personalized medicine -- How much can drugs cost? -- Modeling drug discovery until 2025 -- Drug development models between 2010 & 2025.
0
SUMMARY OR ABSTRACT
Text of Note
"The drug industry is the source of practically all approved drugs. Yet, 'Big Pharma' is cutting entire drug R&D programs and staff, and is no longer even trying to provide many of the drugs society needs. There will be few new antibiotics, drugs for Alzheimer's disease, for pain and for many other diseases unless governments intervene to ensure the right scientific research is conducted and the necessary trials are funded. Incentives are needed for the pharma industry to change its current research and business path. This thought-provoking book is the first to: explain what it means for scientists and society; determine what to do to make sure the industry responds to society's needs and remains commercially attractive; and provide cost-effective business solutions to the dilemmas facing the drug industry, governments, and society."--Back cover.
TOPICAL NAME USED AS SUBJECT
Drug development.
Drugs-- Design.
Drug Discovery-- trends.
Drug Industry-- economics.
DEWEY DECIMAL CLASSIFICATION
Number
615
.
19
Edition
23
LIBRARY OF CONGRESS CLASSIFICATION
Class number
RM
301
.
25
Book number
.
B37
2013
OTHER CLASS NUMBERS
Class number
2013
G-572
Class number
QV
745
PERSONAL NAME - PRIMARY RESPONSIBILITY
Bartfai, Tamas
PERSONAL NAME - ALTERNATIVE RESPONSIBILITY
Lees, Graham V.
ORIGINATING SOURCE
Date of Transaction
20140117044437.0
Cataloguing Rules (Descriptive Conventions))
rda
ELECTRONIC LOCATION AND ACCESS
Electronic name
مطالعه متن کتاب [Book]
Y
